Sermorelin, GHRP-6, GHRP-2 9mg (Blend)

70.00 USD

Availability: In stock

FREE Shipping for orders over $200 (USA Only)

$15.00 Flat Rate Shipping Worldwide (Most Countries) 

*Includes one 30mL Bacteriostatic Water with orders over $300.00

$70.00
  • Buy 5 for $65.00 each and save 8%
  • Buy 10 for $63.00 each and save 10%
Sermorelin 3mg, GHRP-6 3mg, GHRP-2 3mg (9mg Total Blend)

Sermorelin, GHRP-6, GHRP-2 9mg (Blend)

Product Usage: THIS PRODUCT IS INTENDED AS A RESEARCH CHEMICAL ONLY. This designation allows the use of research chemicals strictly for in vitro testing and laboratory experimentation only. All product information available on this website is for educational purposes only. Bodily introduction of any kind into humans or animals is strictly forbidden by law. This product should only be handled by licensed, qualified professionals. This product is not a drug, food, or cosmetic and may not be misbranded, misused or mislabled as a drug, food or cosmetic.

A combination of growth hormone (GH) releasing peptides can lead to tremendous increases in GH levels, but such a process generally only requires a growth hormone releasing hormone (GHRH) analogue like sermorelin and a growth hormone secretagogue/ghrelin analogue like GHRP-2 or GHRP-6. Combining all three isn’t likely to cause a proportionally greater increase in GH hormone levels, but are other reasons to utilize such a combination.

Sermorelin is an excellent GHRH analogue with strong GH releasing action and very few off-target effects. In addition., the peptide has been found in animal studies to improve heart health, increase bone density, improve renal function, and possibly even fight off the effects of dementia. GHRP-2 not only helps to build muscle, but has been shown to enhance muscle structure as well[1]–[3]. It is also a strong appetite stimulant, improves heart function, boosts immune function, reduces pain perception, and benefits sleep quality[4]–[10]. GHRP-6 has been shown to protect brain tissue, enhance memory, boost wound repair, and modulate reward-seeking behavior[11]–[21].

The above list of effects demonstrates both common overlap as well as complimentary features for the peptides above. By combining a GHRH analogue and a ghrelin analogue, maximal growth hormone release is achieved. By combining all three peptides in the correct way (e.g. alternating GHRP-6 with GHRP-2 dosing), it is possible to also amplify the peptides’ secondary effects and achieve additional benefits such as enhanced bone deposition, improved brain protection, and more.

Resources

  • [1] R. Hu et al., “Effects of GHRP-2 and Cysteamine Administration on Growth Performance, Somatotropic Axis Hormone and Muscle Protein Deposition in Yaks (Bos grunniens) with Growth Retardation,” PloS One, vol. 11, no. 2, p. e0149461, 2016.
  • [2] D. Yamamoto et al., “GHRP-2, a GHS-R agonist, directly acts on myocytes to attenuate the dexamethasone-induced expressions of muscle-specific ubiquitin ligases, Atrogin-1 and MuRF1,” Life Sci., vol. 82, no. 9–10, pp. 460–466, Feb. 2008. [PubMed]
  • [3] L. T. Phung et al., “The effects of growth hormone-releasing peptide-2 (GHRP-2) on the release of growth hormone and growth performance in swine,” Domest. Anim. Endocrinol., vol. 18, no. 3, pp. 279–291, Apr. 2000.[PubMed]
  • [4] B. Laferrère, C. Abraham, C. D. Russell, and C. Y. Bowers, “Growth hormone releasing peptide-2 (GHRP-2), like ghrelin, increases food intake in healthy men,” J. Clin. Endocrinol. Metab., vol. 90, no. 2, pp. 611–614, Feb. 2005.[PubMed]
  • [5] B. Laferrère, A. B. Hart, and C. Y. Bowers, “Obese subjects respond to the stimulatory effect of the ghrelin agonist growth hormone-releasing peptide-2 on food intake,” Obes. Silver Spring Md, vol. 14, no. 6, pp. 1056–1063, Jun. 2006. [PMC]
  • [6] G. Muccioli et al., “Growth hormone-releasing peptides and the cardiovascular system,” Ann. Endocrinol., vol. 61, no. 1, pp. 27–31, Feb. 2000. [PubMed]
  • [7] V. Bodart et al., “Identification and characterization of a new growth hormone-releasing peptide receptor in the heart,” Circ. Res., vol. 85, no. 9, pp. 796–802, Oct. 1999. [PubMed]
  • [8] D. D. Taub, W. J. Murphy, and D. L. Longo, “Rejuvenation of the aging thymus: growth hormone-mediated and ghrelin-mediated signaling pathways,” Curr. Opin. Pharmacol., vol. 10, no. 4, pp. 408–424, Aug. 2010. [PubMed]
  • [9] G. Copinschi et al., “Prolonged oral treatment with MK-677, a novel growth hormone secretagogue, improves sleep quality in man,” Neuroendocrinology, vol. 66, no. 4, pp. 278–286, Oct. 1997. [PubMed]
  • [10] P. Zeng et al., “Ghrelin receptor agonist, GHRP-2, produces antinociceptive effects at the supraspinal level via the opioid receptor in mice,” Peptides, vol. 55, pp. 103–109, May 2014. [PubMed]
  • [11] C.-C. Huang, D. Chou, C.-M. Yeh, and K.-S. Hsu, “Acute food deprivation enhances fear extinction but inhibits long-term depression in the lateral amygdala via ghrelin signaling,” Neuropharmacology, vol. 101, pp. 36–45, Feb. 2016. [PubMed]
  • [12] S. Beheshti and S. Shahrokhi, “Blocking the ghrelin receptor type 1a in the rat brain impairs memory encoding,” Neuropeptides, vol. 52, pp. 97–102, Aug. 2015. [Science Direct]
  • [13] K. Tóth, K. László, and L. Lénárd, “Role of intraamygdaloid acylated-ghrelin in spatial learning,” Brain Res. Bull., vol. 81, no. 1, pp. 33–37, Jan. 2010. [PubMed]
  • [14] N. Subirós et al., “Assessment of dose-effect and therapeutic time window in preclinical studies of rhEGF and GHRP-6 coadministration for stroke therapy,” Neurol. Res., vol. 38, no. 3, pp. 187–195, Mar. 2016. [PubMed]
  • [15] S. J. Spencer, A. A. Miller, and Z. B. Andrews, “The Role of Ghrelin in Neuroprotection after Ischemic Brain Injury,” Brain Sci., vol. 3, no. 1, pp. 344–359, Mar. 2013. [PMC]
  • [16] Y. Suda et al., “Down-regulation of ghrelin receptors on dopaminergic neurons in the substantia nigra contributes to Parkinson’s disease-like motor dysfunction,” Mol. Brain, vol. 11, no. 1, p. 6, 20 2018. [BMC]
  • [17] Y. Mendoza Marí et al., “Growth Hormone-Releasing Peptide 6 Enhances the Healing Process and Improves the Esthetic Outcome of the Wounds,” Plastic Surgery International, 2016. [Online]. Available: https://www.hindawi.com/journals/psi/2016/4361702/. [Accessed: 23-May-2019]. [PMC]
  • [18] M. Fernández-Mayola et al., “Growth hormone-releasing peptide 6 prevents cutaneous hypertrophic scarring: early mechanistic data from a proteome study,” Int. Wound J., vol. 15, no. 4, pp. 538–546, Aug. 2018. [PubMed]
  • [19] J. Berlanga et al., “Growth-hormone-releasing peptide 6 (GHRP6) prevents oxidant cytotoxicity and reduces myocardial necrosis in a model of acute myocardial infarction,” Clin. Sci. Lond. Engl. 1979, vol. 112, no. 4, pp. 241–250, Feb. 2007. [PubMed]
  • [20] L. Hyland et al., “Central ghrelin receptor stimulation modulates sex motivation in male rats in a site dependent manner,” Horm. Behav., vol. 97, pp. 56–66, 2018. [Science Direct]
  • [21] H.-J. Huang et al., “The protective effects of Ghrelin/GHSR on hippocampal neurogenesis in CUMS mice,” Neuropharmacology, May 2019. [PubMed]